Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer

NCT00890903 is registered in ClinicalTrials.gov with Pierre Fabre Pharma GmbH as lead sponsor.

NCT NCT00890903
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00890903 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Usage of Vinorelbin ORAL (Navelbine® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer
Lead sponsor
Pierre Fabre Pharma GmbH
Phase
Observational
Overall status
Completed
Start date
March 31, 2009
Completion date
April 30, 2012
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer, non small cell lung carcinoma